CMML: a biologically distinct myeloproliferative disease.

Research output: Contribution to journalReview article

Abstract

Chronic myelomonocytic leukemia (CMML) is a myeloproliferative disorder with unique characteristics. Dysplasia is usually present in the bone marrow, thus CMML has usually been classified as a myelodysplastic syndrome. The recent World Health Organization classification of myeloid malignancies proposes to classify CMML into a new category of myelodysplastic syndromes and myeloproliferative disorders. A new prognostic score has also been developed exclusively for patients with CMML that recognizes four groups with distinct prognoses. Significant biologic findings in the recent months include the recognition of the importance of angiogenesis in CMML with a possible autocrine role for vascular endothelial growth factor, and the further understanding of the role of tyrosine kinase fusion genes and activation in some patients with CMML Therapeutic discoveries have been hampered by the paucity of studies looking specifically at CMML Among agents with potential significant activity are imatinib mesylate (for patients with platelet-derived growth factor beta receptor-associated fusion genes), hypomethylating agents, antiangiogenic agents, farnesyltransferase inhibitors, and topoisomerase I inhibitors. Future studies should consider CMML as a separate entity to promote a better understanding and identify more effective therapy for patients with this disease.

Original languageEnglish (US)
Pages (from-to)202-208
Number of pages7
JournalCurrent hematology reports
Volume2
Issue number3
StatePublished - May 2003
Externally publishedYes

Fingerprint

Leukemia, Myelomonocytic, Chronic
Myeloproliferative Disorders
Myelodysplastic Syndromes
Topoisomerase I Inhibitors
Platelet-Derived Growth Factor beta Receptor
Farnesyltranstransferase
Angiogenesis Inhibitors
Gene Fusion
Protein-Tyrosine Kinases
Vascular Endothelial Growth Factor A
Transcriptional Activation
Bone Marrow

ASJC Scopus subject areas

  • Hematology

Cite this

CMML : a biologically distinct myeloproliferative disease. / Cortes, Jorge.

In: Current hematology reports, Vol. 2, No. 3, 05.2003, p. 202-208.

Research output: Contribution to journalReview article

@article{eff638fe15a44431a1050c0996904892,
title = "CMML: a biologically distinct myeloproliferative disease.",
abstract = "Chronic myelomonocytic leukemia (CMML) is a myeloproliferative disorder with unique characteristics. Dysplasia is usually present in the bone marrow, thus CMML has usually been classified as a myelodysplastic syndrome. The recent World Health Organization classification of myeloid malignancies proposes to classify CMML into a new category of myelodysplastic syndromes and myeloproliferative disorders. A new prognostic score has also been developed exclusively for patients with CMML that recognizes four groups with distinct prognoses. Significant biologic findings in the recent months include the recognition of the importance of angiogenesis in CMML with a possible autocrine role for vascular endothelial growth factor, and the further understanding of the role of tyrosine kinase fusion genes and activation in some patients with CMML Therapeutic discoveries have been hampered by the paucity of studies looking specifically at CMML Among agents with potential significant activity are imatinib mesylate (for patients with platelet-derived growth factor beta receptor-associated fusion genes), hypomethylating agents, antiangiogenic agents, farnesyltransferase inhibitors, and topoisomerase I inhibitors. Future studies should consider CMML as a separate entity to promote a better understanding and identify more effective therapy for patients with this disease.",
author = "Jorge Cortes",
year = "2003",
month = "5",
language = "English (US)",
volume = "2",
pages = "202--208",
journal = "Current hematology reports",
issn = "1540-3408",
number = "3",

}

TY - JOUR

T1 - CMML

T2 - a biologically distinct myeloproliferative disease.

AU - Cortes, Jorge

PY - 2003/5

Y1 - 2003/5

N2 - Chronic myelomonocytic leukemia (CMML) is a myeloproliferative disorder with unique characteristics. Dysplasia is usually present in the bone marrow, thus CMML has usually been classified as a myelodysplastic syndrome. The recent World Health Organization classification of myeloid malignancies proposes to classify CMML into a new category of myelodysplastic syndromes and myeloproliferative disorders. A new prognostic score has also been developed exclusively for patients with CMML that recognizes four groups with distinct prognoses. Significant biologic findings in the recent months include the recognition of the importance of angiogenesis in CMML with a possible autocrine role for vascular endothelial growth factor, and the further understanding of the role of tyrosine kinase fusion genes and activation in some patients with CMML Therapeutic discoveries have been hampered by the paucity of studies looking specifically at CMML Among agents with potential significant activity are imatinib mesylate (for patients with platelet-derived growth factor beta receptor-associated fusion genes), hypomethylating agents, antiangiogenic agents, farnesyltransferase inhibitors, and topoisomerase I inhibitors. Future studies should consider CMML as a separate entity to promote a better understanding and identify more effective therapy for patients with this disease.

AB - Chronic myelomonocytic leukemia (CMML) is a myeloproliferative disorder with unique characteristics. Dysplasia is usually present in the bone marrow, thus CMML has usually been classified as a myelodysplastic syndrome. The recent World Health Organization classification of myeloid malignancies proposes to classify CMML into a new category of myelodysplastic syndromes and myeloproliferative disorders. A new prognostic score has also been developed exclusively for patients with CMML that recognizes four groups with distinct prognoses. Significant biologic findings in the recent months include the recognition of the importance of angiogenesis in CMML with a possible autocrine role for vascular endothelial growth factor, and the further understanding of the role of tyrosine kinase fusion genes and activation in some patients with CMML Therapeutic discoveries have been hampered by the paucity of studies looking specifically at CMML Among agents with potential significant activity are imatinib mesylate (for patients with platelet-derived growth factor beta receptor-associated fusion genes), hypomethylating agents, antiangiogenic agents, farnesyltransferase inhibitors, and topoisomerase I inhibitors. Future studies should consider CMML as a separate entity to promote a better understanding and identify more effective therapy for patients with this disease.

UR - http://www.scopus.com/inward/record.url?scp=0141956034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141956034&partnerID=8YFLogxK

M3 - Review article

C2 - 12901341

AN - SCOPUS:0141956034

VL - 2

SP - 202

EP - 208

JO - Current hematology reports

JF - Current hematology reports

SN - 1540-3408

IS - 3

ER -